Appendix 1: Syndrome-Specific Growth Charts
|
|
- Linette Newton
- 5 years ago
- Views:
Transcription
1 Appendix 1: Syndrome-Specific Growth Charts Figure A1.1 Height centiles for girls with untreated Turner syndrome aged 1 20 years. The gray-shaded area represents the 3rd to 97th centiles for normal girls. Pubertal staging is for normal girls. Adapted from Lyon A, Preece M, Grant D. Growth curves for girls with Turner syndrome. Arch Dis Child 1985; 60:
2 Appendix 1: Syndrome-Specific Growth Charts Figure A1.2 Height and weight centiles for boys with trisomy 21 syndrome aged 3 36 months. Adapted from Cronk C, Crocker A, Peushel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:
3 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.3 Height and weight centiles for boys with trisomy 21 syndrome aged 2 18 years. The gray-shaded areas represent the comparable values for the 3rd to 97th centiles for normal children. Adapted from Cronk C, Crocker A, Peuschel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:
4 Appendix 1: Syndrome-Specific Growth Charts Figure A1.4 Height and weight centiles for girls with trisomy 21 syndrome aged 3 36 months. Adapted from Cronk C, Crocker A, Peuschel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:
5 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.5 Height and weight centiles for girls with trisomy 21 syndrome aged 2 18 years. The gray-shaded areas represent the comparable values for the 3rd to 97th centiles for normal children. Adapted from Cronk C, Crocker A, Peuschel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:
6 Appendix 1: Syndrome-Specific Growth Charts Figure A1.6 Height centiles for boys with Noonan syndrome aged 0 18 years compared with normal values (dashed lines). The data were obtained from 64 Noonan syndrome males in a collaborative retrospective review. Adapted from Witt D, Keena B, Hall J et al. Growth curves for height in Noonan syndrome. Clin Genet 1986; 30: Figure A1.7 Height centiles for girls with Noonan syndrome aged 0 18 years compared with normal values (dashed lines). The data were obtained from 48 Noonan syndrome females in a collaborative retrospective review. Adapted from Witt D, Keena B, Hall J et al. Growth curves for height in Noonan syndrome. Clin Genet 1986; 30:
7 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.8 Height centiles for boys with Silver Russell syndrome. The gray-shaded area indicates normal boys 2 standard deviations (SD). Adapted from Wollman H, Kirchner T, Enders H et al. Growth and symptoms in Silver Russell syndrome: review on the basis of 386 patients. Eur J pediatr 1995; 154: Figure A1.9 Height centiles for girls with Silver Russell syndrome. The gray-shaded area indicates normal girls 2 standard deviations (SD). Adapted from Wollman H, Kirchner T, Enders H et al. Growth and symptoms in Silver Russell syndrome: review on the basis of 386 patients. Eur J pediatr 1995; 154:
8 Appendix 1: Syndrome-Specific Growth Charts Figure A1.10 Height centiles for boys with achondroplasia (mean 2 SD) compared with normal standard curves (dashed lines). Data derived from 189 males. Adapted from Horton W, Rotter J, Rimoin D et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93: Figure A1.11 Head circumference centiles for boys with achondroplasia compared with normal curves (dashed lines). Data derived from 114 males. Adapted from Horton W, Rotter J, Rimoin D et al. Standard gowth curves for achondroplasia. J Pediatr 1978; 93:
9 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.12 Height centiles for girls with achondroplasia (mean 2 SD) compared with normal standard curves (dashed lines). Data derived from 214 females. Adapted from Horton W, Rotter J, Rimoin D et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93: Figure A1.13 Head circumference centiles for girls with achondroplasia compared with normal curves (dashed lines). Data derived from 145 females. Adapted from Horton W, Rotter J, Rimoin D et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93:
10 Appendix 1: Syndrome-Specific Growth Charts Figure A1.14 Linear growth in hypocondroplasic boys (solid line). Adapted from Appan S, Laurent S, Champan M et al. Growth and growth hormone therapy in hypochondroplasia. Acta paediatr Scand 1990; 79: Figure A1.15 Linear growth in hypocondroplasic girls (solid line). Adapted from Appan S, Laurent S, Champan M et al. Growth and growth hormone therapy in hypochondroplasia. Acta paediatr Scand 1990; 79:
11 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.16 Standardized curves for height in Prader Willi syndrome (PWS) in male patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88: Figure A1.17 Standardized curves for height in Prader Willi syndrome (PWS) in female patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88:
12 Appendix 1: Syndrome-Specific Growth Charts Figure A1.18 Standardized curves for weight in Prader Willi syndrome (PWS) in male patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88: Figure A1.19 Standardized curves for weight in Prader Willi syndrome (PWS) in female patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88:
Special Needs Growth Charts
Special Needs Growth Charts WIC staff are encouraged to review the online module entitled The CDC Growth Charts for Children with Special Health Care Needs. The CDC module was revised by the University
More informationAPPENDIX I / Nutritional Assessment 845
APPENDIX I / Nutritional Assessment 845 Figure I-37 Weight-for-age percentile curves for girls with cerebral palsy (solid line) versus healthy individuals (broken line) ( to 12 months). (Reproduced from
More informationD own s syndrome (DS) is the most common chromosomal
97 ORIGINAL ARTICLE Growth charts for Down s syndrome from birth to 18 years of age Å Myrelid, J Gustafsson, B Ollars, G Annerén... See end of article for authors affiliations... Correspondence to: Dr
More informationMODULE 1: Growth Assessment
MODULE 1: Growth Assessment LEARNING OBJECTIVES After completing this module, you will have the skills and resources to: Describe techniques to obtain accurate anthropometric data for children with special
More informationGrowth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A
Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Record Status This is a critical abstract of an economic
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationCIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -
Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed
More informationDiet in. Chris Smith Senior Paediatric Dietitian
Diet in Chris Smith Senior Paediatric Dietitian What do you recommend? How many calories does my child need? How often should I weigh my child and how do I know if the growth is good? What are the answers?
More informationHUMAN GROWTH HORMONE GENOTROPIN
Drug Prior Authorization Guideline HUMAN GROWTH HORMONE GENOTROPIN (somatropin) PA9728 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes Additional Information: Medicare
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationJanice Scott MS, RD, CSP, LD Clinical Nutrition Manager Texas Scottish Rite Hospital for Children
Janice Scott MS, RD, CSP, LD Clinical Nutrition Manager Texas Scottish Rite Hospital for Children Nutrition and Disability are intimately linked. Malnutrition can directly cause or contribute to disability
More informationEVALUATION OF SHORT NECK: NEW NECK LENGTH PERCENTILES AND LINEAR CORRELATIONS WITH HEIGHT AND SITTING HEIGHT
EVALUATION OF SHORT NECK: NEW NECK LENGTH PERCENTILES AND LINEAR CORRELATIONS WITH HEIGHT AND SITTING HEIGHT P.V. Mahajan B.A. Bharucha ABSTRACT Qualitative impressions of neck length are often used as
More informationHow to approach a child with growth concern
How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand
More information4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!
Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management Kent Reifschneider, MD CHKD / EVMS Norfolk, VA Conflict of Interest Speaker bureau and advisor for Pfizer Board member of The
More informationhypothyroidism Growth in early treated congenital ORIGINAL ARTICLES
464 Archives of Disease in Childhood 1994; 70: 464-468 ORIGINAL ARTICLES Institute of Child Health, London D B Grant Correspondence to: Dr D B Grant, Hospital for Sick Children, Great Ormond Street, London
More informationAmerican Journal of Medical Genetics 91: (2000)
American Journal of Medical Genetics 91:298 304 (2000) Phenotypic Heterogeneity of Growth and Psychometric Intelligence in Prader-Willi Syndrome: Variable Expression of a Contiguous Gene Syndrome or Parent
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationDevelopment of disease-specific growth charts in Turner syndrome and Noonan syndrome
Review article https://doi.org/10.6065/apem.2017.22.4.240 Ann Pediatr Endocrinol Metab 2017;22:240-246 Development of disease-specific growth charts in Turner syndrome and Noonan syndrome Tsuyoshi Isojima,
More informationStandard Growth Curves in Prader-Willi Syndrome in Japan
Clin Pediatr Endocrinol 1993;2 (1): 39-43 Copyright (C)1993 by The Japanese Society for Pediatric End ocrinology Standard Growth Curves in Prader-Willi Syndrome in Japan Toshiro Nagai, Yutaka Tsuchiya,
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationNational Screening Committee. Child Health Sub-Group Report Growth Disorders
National Screening Committee Child Health Sub-Group Report Growth Disorders September 2004 Growth Disorders The condition Growth disorders. There are many conditions that cause abnormally slow or fast
More informationAssessing Overweight in School Going Children: A Simplified Formula
Journal of Applied Medical Sciences, vol. 4, no. 1, 2015, 27-35 ISSN: 2241-2328 (print version), 2241-2336 (online) Scienpress Ltd, 2015 Assessing Overweight in School Going Children: A Simplified Formula
More informationIntrauterine Growth Retardation or Small Gestational Age. Series N.14
Intrauterine Growth Retardation or Small Gestational Age Series N.14 Patient s Guide Average Readability Leaflet Intrauterine Growth Retardation- Series 14 (Revised August 2006) This leaflet was produced
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:
More informationWorld Health Organization Growth Standards. BC Training Module PowerPoint Speaking Notes
World Health Organization Growth Standards BC Training Module PowerPoint Speaking Notes May 30, 2011 British Columbia WHO Growth Chart Training June 2011 Page 1 PowerPoint Speaking Notes Slide 1 Title
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First
More information3/16/2018. Normal patterns of growth Definition and causes of FTT Medical evaluation and management Effects of FTT Early intervention
WI CAN Educational Series Hillary W. Petska, MD, MPH, FAAP Child Advocacy and Protection Services Children s Hospital of Wisconsin Normal patterns of growth Definition and causes of FTT Medical evaluation
More informationGrowth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome
Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome Merlin G. Butler, MD, PhD a, Jaehoon Lee, PhD b, Ann M. Manzardo, PhD a, June-Anne Gold, MD c, Jennifer L. Miller, MD d, Virginia Kimonis,
More informationEndocrine: Precocious Puberty Health care guidelines for Spina Bifida
Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Precocious Puberty Primary outcome: Timely assessment, identification, appropriate referral, and management of precocious puberty.
More informationFailure to Thrive Severity Determination by New Design Curves in Standard Growth Charts
Failure to Thrive Severity Determination by New Design Curves in Standard Growth Charts Firouzeh Hosseini *1, Babak Borzouei *2, and Mehrangiz Vahabian 2 1 Department of Pediatrics, Besat Hospital, Hamedan
More informationBlood pressure charts for pediatrics
Blood pressure charts for pediatrics Blood pressure screening is essential throughout life. Adult blood pressure assessments have static thresholds of 140/90 for hypertension and 90/60 for hypotension
More informationOZGROW Report 2009/2010
OZGROW Report 2009/2010 GH therapy in Australia As of May 2010 there are 1636 children receiving GH treatment in Australia under the PBS. The Department of Health and Ageing s (DoHA) indication for GH
More informationWHO Child Growth Standards
WHO Child Growth Standards Implications for everyday practice Dr Mercedes de Onis Department of Nutrition World Health Organization Geneva, Switzerland 1 year 2 years 3 years 4 years 5 years WHO Child
More informationGROWTH ASSESSMENT AND GROWTH DISORDERS. IAP UG Teaching slides
GROWTH ASSESSMENT AND GROWTH DISORDERS 1 GROWTH PARAMETERS TO BE MONITORED Birth 2 years: Weight, length & head circumference at birth, immunization contacts at 6, 10, 14 weeks, 9 months, 15 months & 18
More informationBody Composition and Fatness Patterns in Prader-Willi Syndrome: Comparison with Simple Obesity
Original Research as Short Communication Body Composition and Fatness Patterns in Prader-Willi Syndrome: Comparison with Simple Obesity Mariana F. Theodoro, Zohreh Talebizadeh, and Merlin G. Butler Abstract
More informationGrowth variations and secular trend in Argentina
XIV Congreso Internacional de Auxología «Por un crecimiento saludable en un mundo mejor» CRECIMIENTO EN PAÍSES LATINOAMERICANOS: SIMILITUDES Y DIFERENCIAS Growth variations and secular trend in Argentina
More informationSomatostatin Analog and Estrogen Treatment in a Tall Girl
Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,
More informationGenotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,
Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Human Growth Hormone Somatropin (Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Serostim, Saizen, Zomacton/TevTropin,
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationWeight, height and BMI references in Elazığ: an east Anatolian city
The Turkish Journal of Pediatrics 2011; 53: 404-412 Original Weight, height and BMI references in Elazığ: an east Anatolian city Edibe Pirinçci 1, M Mümtaz Mazıcıoğlu 2, Ufuk Berberoğlu 3, Yasemin Açık
More informationAge-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height 1 3
Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height 1 3 Julie E Hoover-Fong, Kerry J Schulze, John McGready, Hillary Barnes, and Charles I Scott
More informationThis CNE activity is supported by an educational grant from Novo Nordisk Inc.
This CNE activity is supported by an educational grant from Novo Nordisk Inc. Objectives Differentiate between normal growth variants and growth variants that are linked to a disorder Describe the process
More informationGrowth Charts for Children With Down Syndrome in the United States
Growth Charts for Children With Down Syndrome in the United States Babette S. Zemel, PhD a,b, Mary Pipan, MD b,c, Virginia A. Stallings, MD a,b, Waynitra Hall, MS a, Kim Schadt, MSN b,c, David S. Freedman,
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationCommittee Approval Date: January 19, 2015 Next Review Date: January 2016
Medication Policy Manual Policy No: dru126 Topic: Increlex, mecasermin Date of Origin: January 3, 2006 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: February
More informationThe science behind igro
The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts
More informationMonth/Year of Review: September 2013 Date of Last Review: September 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationSCRIPT: Module 3. Interpreting the WHO Growth Charts for Canada SLIDE NUMBER SLIDE SCRIPT
SCRIPT: Module 3 Interpreting the WHO Growth Charts for Canada 1 Welcome Welcome to Module 3 - Interpreting the WHO Growth Charts for Canada. Each of the modules in this training package has been designed
More informationand LHRH Analog Treatment in
Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National
More informationPFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPaula van Dommelen. Evidence-based referral criteria in growth monitoring
Paula van Dommelen Evidence-based referral criteria in growth monitoring Evidence-based referral criteria in growth monitoring Paula van Dommelen Evidence-based referral criteria in growth monitoring ISBN
More informationI n the diagnostic work-up of children with exceptionally
87 ORIGINAL ARTICLE Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders A M Fredriks, S van Buuren,
More informationGH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK
GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK Overview GH therapy Indications Specific advantages Extra precautions Case scenarios without
More informationDistribution of T4 TSH Values in Children - the Shifa Experience
Distribution of T4 TSH Values in Children - the Shifa Experience Y. Najam,M. Khan ( Departments of Pediatrics, Shifa International Hospital, Islamabad. ) F. Ilahi,A. Alam ( Departments of Biochemistry,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM
More informationEvidence-based referral criteria in growth monitoring
Evidence-based referral criteria in growth monitoring Paula van Dommelen Evidence-based referral criteria in growth monitoring Evidence-based verwijscriteria voor groei (met een samenvatting in het Nederlands)
More informationA total of 3061 children, 1528 boys and 1533 girls. aged 4-19 years, were included in the analysis. Table 1. Does your child have: 1 Asthma ( ) ( )
Archives of Disease in Childhood, 1989, 64, 96-102 Growth and other factors flow rate affecting peak expiratory J W K CARSON,* H HOEY,*t AND M R H TAYLOR*t *National Children's Hospital and tdepartment
More information1389 (54 )1 - *** *** *** ** *** * * ** *** ( ) : /8/26 : 88/2/1 : (WC) (BMI) :.. (CVD) - : :
JQUMS, Vol.14, No.1, Spring 2010 18 Predicting risk factors of cardiovascular disease according to anthropometric measures in children and adolescents R Kelishadi* M Hashemipour** Z Faghihimani*** E Nazemi***
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationPolicies, Procedures, Guidelines and Protocols
Policies, Procedures, Guidelines and Protocols Document Details Title Sleep Disordered Breathing Guideline Trust Ref No 2073-38165 Local Ref (optional) Main points the document covers Diagnosis, investigation
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/71147
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must
More informationWorld Health Organization Growth Standards. First Nations and Inuit Health Alberta Region: Training Module May 2011
World Health Organization Growth Standards First Nations and Inuit Health Alberta Region: Training Module May 2011 Acknowledgements First Nation and Inuit Health Alberta Region would like to thank the
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 15 November 2007 Doc. Ref. EMEA/CHMP/EWP/517497/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL EVALUATION OF MEDICINAL PRODUCTS USED
More informationGrowth after renal transplants
Archives of Disease in Childhood, 1983, 58, 110-114 Growth after renal transplants M BOSQUE, A MUNIAN, M BEWICK, G HAYCOCK, AND C CHANTLER Evelina Children's Department, Guy's Hospital, London SUMMARY
More informationGrowth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5
Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationOBJECTIVES OVERVIEW 5/30/2012. IL WIC Program Risk Factor Changes July 1, 2012
IL WIC Program Risk Factor Changes July 1, 2012 AUTOPLOT OBJECTIVES State the Center for Disease Control (CDC) new growth chart recommendations for birth to 24 months incorporating the WHO growth standards.
More informationGrowth and metabolic consequences of growth hormone treatment in prepubertal short normal children
Archives of Disease in Childhood 1994; 71: 21-26 Southampton University Hospitals Trust, Tremona Road, Southampton S9 4XY, Department of Child Health E S McCaughey J Mulligan L D Voss Department of Paediatrics
More informationThe Development of Reference Values for Waist Circumference, Waist Hip and Waist Height Ratios in Egyptian Adolescents.
Curr Pediatr Res ; (1&2): - ISSN 09-9032 www.currentpediatrics.com The Development of Reference Values for Waist Circumference, Waist Hip and Waist Height Ratios in Egyptian Adolescents. Alaa Youssef Ahmed
More informationNational Child Measurement Programme Changes in children s body mass index between 2006/07 and 2010/11
National Child Measurement Programme Changes in children s body mass index between 2006/07 and 2010/11 Delivered by NOO on behalf of the Public Health Observatories in England Published: March 2012 NOO
More informationBody Mass Index reference curves for children aged 3 19 years from Verona, Italy
European Journal of Clinical Nutrition (1997) 51, 6±10 ß 1997 Stockton Press All rights reserved 0954±3007/97 $12.00 Body Mass Index reference curves for children aged 3 19 years from Verona, Italy A Luciano
More informationPubertal Development in Japanese Boys
Clin Pediatr Endocrinol 1993; (SuPP13): 7-14 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Pubertal Development in Japanese Boys Kenji Fujieda, M.D., Ph. D. Department of Pediatrics,
More informationLinear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure
Linear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure Terri H. Lipman PhD, CRNP, FAAN University of Pennsylvania, School of Nursing Children s Hospital of Philadelphia Growth
More informationStudy of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents
Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Prof. Azza Abdel Shaheed Prof. of Child Health NRC National Research Centre Egypt Prevalence of childhood
More informationJudith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction
Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year
More informationThe Presence of Normal Levels of Serum Immunoreactive Insulin-like Growth Factor 2 (IGF-2) in Patients with Down's Syndrome
Upsala J Med Sci 89: 274278, 1984 The Presence of Normal Levels of Serum Immunoreactive Insulin-like Growth Factor 2 (IGF-2) in Patients with Down's Syndrome Goran Annerkn,' Gosta Enberg,' and Vicki R.
More informationGrowth hormone treatment in young children with Down s syndrome: evects on growth and psychomotor development
334 Genetics and Pathology, Unit of Clinical Genetics, Uppsala University Children s Hospital, S-751 85 Uppsala, Sweden G Annerén Paediatrics, Uppsala University Children s Hospital T Tuvemo J Gustafsson
More informationStudent Guide Module 8: Nutrition and Malnutrition
Student Guide Module 8: Nutrition and Malnutrition Objectives of the station Plan and develop measures to assess the nutritional status of populations displaced by disasters, and to ensure optimal nutritional
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationMonitoring treatment in congenital adrenal
Archives of Disease in Childhood, 1989, 64, 1235-1239 Monitoring treatment in congenital adrenal hyperplasia S APPAN, P C HINDMARSH, AND C G D BROOK Endocrine Unit, Middlesex Hospital, London SUMMARY We
More informationCh 7 Extending Mendelian Genetics
Ch 7 Extending Mendelian Genetics Studying Human Genetics A pedigree is a chart for tracing genes in a family. Used to determine the chances of offspring having a certain genetic disorder. Karyotype=picture
More informationCritical Growth Phases for Adult Shortness
American Journal of Epidemiology Copyright 2000 by The Johns Hopkins University chool of Hygiene and Public Health All rights reserved Vol. 2, o. 2 Printed in U..A. Critical Growth Phases for Adult hortness
More informationGrowth promoting treatment: When discretion is the better part of value
Growth promoting treatment: When discretion is the better part of value David B. Allen, MD Professor of Pediatrics University of Wisconsin School of Medicine and Public Health Head of Division of Diabetes
More informationExpert Committee Recommendations on the Assessment, Prevention and Treatment of Child and Adolescent Overweight and Obesity
Expert Committee Recommendations on the Assessment, and Treatment of Child and Adolescent Over and Obesity - 2007 - An Implementation Guide from the Childhood Obesity Action Network - Overview: In 2005,
More informationEffect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome
ORIGINAL ARTICLE Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome Ping-Yi Hsu, Yi-Ching Tung, Wen-Yu Tsai,* Jing-Sheng Lee, Pei-Hung Hsiao Background/Purpose: Short stature
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More information